Clinical trial
Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer
NCT00032188 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00032188 |
|---|---|
| Title | Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer |
| Official title | A Randomized Phase II Study Of Interluekin-2 In Combination With Three Different Doses Of Bryostatin In Patients With Renal Cell Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer |
| Intervention type | Biological, Drug, Other |
| Interventions | aldesleukin, bryostatin 1, laboratory biomarker analysis |
| Enrollment | 65 |
| Start date | Jan 1, 2002 |
| Primary completion | Jun 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: